InflaRx’s (IFRX) Sell (E+) Rating Reiterated at Weiss Ratings

Weiss Ratings reissued their sell (e+) rating on shares of InflaRx (NASDAQ:IFRX) in a research note issued to investors on Tuesday,Weiss Ratings reports.

Separately, HC Wainwright initiated coverage on InflaRx in a research report on Tuesday, September 2nd. They set a “buy” rating and a $6.00 price target on the stock. Five equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $6.20.

InflaRx Stock Down 0.8%

Shares of IFRX opened at $1.24 on Tuesday. The business’s 50 day moving average is $1.26 and its two-hundred day moving average is $1.14. InflaRx has a 52-week low of $0.71 and a 52-week high of $2.82. The firm has a market cap of $83.24 million, a price-to-earnings ratio of -1.55 and a beta of 1.40.

InflaRx (NASDAQ:IFRX) last announced its earnings results on Thursday, August 7th. The company reported ($0.24) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.24). The business had revenue of $0.05 million during the quarter, compared to analyst estimates of $0.02 million. On average, equities analysts expect that InflaRx will post -1.04 earnings per share for the current fiscal year.

Institutional Investors Weigh In On InflaRx

Several hedge funds have recently modified their holdings of the stock. Cubist Systematic Strategies LLC lifted its stake in InflaRx by 33.9% in the 1st quarter. Cubist Systematic Strategies LLC now owns 30,053 shares of the company’s stock worth $31,000 after acquiring an additional 7,616 shares in the last quarter. XTX Topco Ltd acquired a new position in InflaRx in the 1st quarter worth about $38,000. Concurrent Investment Advisors LLC acquired a new position in InflaRx in the 2nd quarter worth about $65,000. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in InflaRx by 158.3% in the 2nd quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 150,000 shares of the company’s stock worth $118,000 after purchasing an additional 91,927 shares during the last quarter. Finally, Adage Capital Partners GP L.L.C. acquired a new position in shares of InflaRx during the 2nd quarter valued at about $262,000. 42.39% of the stock is owned by hedge funds and other institutional investors.

About InflaRx

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.